SUMMARY
All neuromuscular blocking agents are capable of liberating histamine from mast cells by a direct pharmacological action.' When injected intradermally this release of histamine is demonstrated by the formation of a local wheal and flare.
In a previous study we found that for atracurium and vecuronium there was a linear relationship between the log concentration of intradermally injected relaxant and the diameter of wheal produced. 2 By comparing the log dose-response relationships we found it possible to quantitate the relative histaminereleasing potency of each drug.
As the relative magnitude of histamineliberating potency is only partially documented for the muscle relaxants,3,4 the purpose of this present study was to determine the relative histamine-releasing potency for six commonly used neuromuscular blocking agents; suxamethonium, alcuronium, d-tubocurarine, atracurium, vecuronium and pancuronium.
SUBJECTS AND METHODS
An initial pilot study was performed on five volunteers to confirm the linear dose-response relationship for each of the tested drugs and to determine suitable drug dilutions giving mean wheal diameters between 6 and 10 mm.
One hundred and twenty volunteer subjects were then randomly designed to one of three study groups, each comprising 20 male and 20 female subjects. None had previously suffered a hypersensitivity response to a muscle relaxant or was taking regular medication that may have interfered with wheal and flare production (i.e. an tihistamines, sympathomimetics, cromoglycate, calcium channel blockers).
Standard commercial formulations of suxamethonium, atracurium, vecuronium, pancuronium, alcuronium and d-tubocurarine were freshly diluted in the concentrations found from the pilot study (shown in Table I ), with 0.9070 physiological saline. Each subject received serial intradermal injections of two agents one into each forearm; O.02ml was injected beginning with the highest concentration on the upper and outer aspects of the anterior forearm, 3 cm below the elbow crease. Five serial injections were made on alternating sides down the forearm at 5 cm intervals.
Subjects were randomly allocated in order that for each drug there was an equal number of male and female subjects and an equal number of left or right forearm injection sites used.
Control injections were made of physiologic saline to rule out dermagraphia and any subject showing marked reactivity to the control is excluded from this study.
Injection sites were examined after 15 minutes. Gentle skin retraction was applied to the skin about the wheal sites allowing their outline to be easily observed, as a pale area, and drawn with a fine ink pen. The recorded wheal outlines were removed with clear adhesive tape and transferred to Imm graph paper. The mean wheal diameter was then derived from wheal area found by the method of counting squares. Table 1 gives the mean wheal diameters for each of the tested drugs together with the calculated least squares regression equations. Figure 1 shows a log linear plot of mean diameter against log concentration with the regression equations plotted in Figure 2 . Analysis of covariance indicated that regression slopes were significantly different (P<O.OOI). d-tubocurarine and atracurium had slopes of 1.9 mml/Ag/ml, 2.2 for alcuronium, and approximately 2.6 for suxamethonium, vecuronium and pancuronium. Because slope variation was significant, regression lines were not compared directly as their relative positions varied according to the wheal diameter selected. We calculated instead, from the regression equations, the log concentration of relaxant which gave a wheal diameter equal to that of the control saline (6.00 mm). These threshold values for wheal formation are given in Table 2 and were used as an index of relative cutaneous histamine- releasing ability. Table 2 also gives the comparative histamine-releasing potency taking into account the varying dosage required for muscle relaxation (calculated by comparing the ratios of the ED95 for neuromuscular blockade and the cutaneous histamine-releasing concentrations). By taking the ratio of relaxant concentration causing 95070 paralysis and the histaminereleasing concentration, an idea of the margin of safety of each drug could be determined: these are shown in Table 3 , for the nondepolarising neuromuscular blocking: agents.
RESULTS
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DISCUSSION
In this study we examined the relative ability of six neuromuscular blocking drugs to induce wheal and flare formation and making the assumption that wheal production is related predominantly to the local release of histamine, we derived their relative cutaneous histaminereleasing ability.
Previous semi-quantitative intradermal studies have suggested the order of histaminereleasing potency but have given little guide as to the relative magnitude of that potency. 5, 6 Weight for weight we found that compared with pancuronium, d-tubocurarine was approximately 23 and atracurium 17 times more potent for cutaneous histamine release. Alcuronium was 1.3 and vecuronium 1.5 times more potent than pancuronium and suxamethonium 10 times less potent.
Relative to the neuromuscular ED95 suxamethonium, pancuronium and vecuronium were of similar potency with alcuronium being 5, atracurium 52 and d-tubocurarine 172 times that of pancuronium.
The data in Table 3 suggests the margin of safety of histamine-releasing concentration relative to the neuromuscular EC 95 . It can be seen that the concentration of relaxant necessary to induce histamine release is, for d-tubocurarine and atracurium, approximately four times that necessary to provide 95070 depression in twitch height. It is understandable therefore why these drugs clinically liberate histamine after bolus injection and why local injection site erythema and wheal formation is common. The margin of safety provided by the other nondepolarising relaxants is considerably greater and therefore they might be expected to release histamine only after large rapid bolus injection and close to the injection site.
After intravenous relaxant injection histamine may be liberated from mast cells distributed throughout the body if the concentration of muscle relaxant is sufficiently high in their immediate environment. Thus it is possible that cutaneous mast cells play only a small part in total body histamine release. However, the data from our cutaneous model is largely consistent with plasma histamine studies after intravenous injection and with the relative incidence of histaminoid reactions seen in clinical practice. 3 ,4,7 It is of note however, that several studies have demonstrated significant release by suxamethonium and one author found that this release could be blocked by pretreatment with pancuronium. 7 If as that study implied histamine liberation is in part caused by muscle fasciculation then clearly that would not be predicted from cutaneous mast cell reactivity.
A nighly significant slope variation was found between the log dose-response relationships. It is possible to consider that this represents a variation in the mechanism of direct histamine release although other factors may include the presence of preservatives and other additives as well as variation in solution pH and tonicity. It is also possible that the muscle relaxants themselves have pharmacological effects which modify the wheal response.
Anaphylactoid reactions to the neuromuscular blocking agents are not uncommon and while some can be ascribed to direct pharmacological mast cell degranulation, the calculated relative order of histamine releasing potency bears little or no relationship with the observed frequency of reactions. In our own regionS as in France,9 suxamethonium is the most common cause of major anaphylactoid reactions and in Australia it is alcuronium. IO We do not therefore believe that direct histamine-releasing ability is closely related to anaphylactoid potential and there is now good evidence to suggest that the majority of major anaphylactoid reactions to the muscle relaxants are true type I IgE mediated hypersensitivity reactions. 11 At present the most useful diagnostic test for relaxant hypersensitivity is the intradermal skin test. By defining the quantitative relationship between wheal formation and drug concentration better diagnostic criteria might be employed in the interpretation of test results. From our own data it is apparent that the criteria proposed by Fisher l2 are conservative and the concentrations he proposes are not significantly confused by normal direct histamine release. This conclusion applies, however, only with an injected volume of O.02ml, the reading taken at 15 minutes, and nonspecific cutaneous reactivity (dermagraphia) carefully excluded.
In conclusion, quantitative intradermal testing provides a simple relatively noninvasive technique for the assessment of pharmacological histamine release; it avoids the interaction of other concurrently administered drugs and may be used for agents of low histamine-releasing ability. During drug development, the technique would be of value to determine direct histamine releasing potential before human intravenous studies are embarked upon.
